His transplant course was complicated by Epstein-Barr virus (EBV) viremia (day + 21, successfully treated with rituximab), immune-mediated cytopenias versus inadequate graft function (beginning at day + 100, refractory to granulocyte-colony stimulating factor (GCSF), corticosteroids, intravenous immunoglobulin (IVIG), plasmapheresis and bortezomib), and right cervical lymphadenopathy concerning for EBV-post-transplant lymphoproliferative disease (day + 188, surgically excised, negative for infection or malignancy). This evidence concerns the gene CSF3 and infection.